CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Pruritus vulvae - Management
Basis for recommendation
These recommendations are based on expert opinion, because CKS found no trial evidence on how pruritus vulvae is best managed in primary care when there is no obvious underlying cause [Doxanakis et al, 2004; Bohl, 2005; Wray, 2009].
- Low potency topical corticosteroids
- CKS identified evidence from one small trial which showed that moderately potent topical corticosteroids are no more effective than placebo for treating pruritus vulvae with an unknown cause [Lagro-Janssen and Sluis, 2009].
- Opinion from CKS expert reviewers was divided regarding the use of low potency topical corticosteroids in women who have pruritus vulvae that has an unknown cause. However, CKS recommends that treatment may be considered on the basis that some women may benefit, and a short trial of low potency corticosteroids is unlikely to cause harm.
© NHS Institute for Innovation and Improvement